
Fertin Pharma has had an eventful 2021.
This much is clear from the company’s latest accounting report, which details an essentially unchanged top-line result of DKK 933m (USD 131m) in 2021 compared to DKK 991m (USD 139m) in 2020, but a dramatic drop on the bottom line.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app